Sumitomo Mitsui Trust Holdings, Inc. Nurix Therapeutics, Inc. Transaction History
Sumitomo Mitsui Trust Holdings, Inc.
- $145 Billion
- Q4 2024
A detailed history of Sumitomo Mitsui Trust Holdings, Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Sumitomo Mitsui Trust Holdings, Inc. holds 789,222 shares of NRIX stock, worth $10.7 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
789,222
Previous 553,251
42.65%
Holding current value
$10.7 Million
Previous $12.4 Million
19.71%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
185Shares Held
70.6MCall Options Held
318KPut Options Held
42.4K-
Black Rock Inc. New York, NY6.82MShares$92.7 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.35MShares$59.1 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.19MShares$57 Million6.18% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$52.8 Million0.81% of portfolio
-
Wellington Management Group LLP Boston, MA3.59MShares$48.7 Million0.01% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $641M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...